Shares of Humacyte Inc (NASDAQ:HUMA) rose 6.1% after the company announced its first commercial sale of Symvess to a U.S. Military Treatment Facility.
The sale was made to a major military medical center located on a large U.S. base, which provides care to around 200,000 active-duty personnel, veterans, and their families. The milestone follows Symvess’s recent inclusion in the Electronic Catalog (ECAT) maintained by the U.S. Defense Logistics Agency.
With ECAT approval, Symvess becomes available for use at approximately 35 military hospitals and 160 facilities operated by the U.S. Department of Veterans Affairs. The product previously received FDA approval in December 2024 for treating extremity vascular trauma.
“We are excited to see the first purchase and use of Symvess by a military treatment facility,” said Dr. Laura Niklason, President and CEO of Humacyte. “We have great interest in improving the medical options available to healthcare professionals treating military personnel and their families, and look forward to advancing our discussions with additional DOD hospitals.”
Humacyte is a commercial-stage biotech firm developing bioengineered human tissue for universal implantation. While Symvess is approved for one specific trauma indication, the company notes that its vessel remains investigational for all other uses and is not yet approved outside that scope.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.